The use of lacZ-transduced tumor cells enhances the sensitivity of micrometastasis detection: A comparative study of gemcitabine treatment efficacy in the mouse LM8 osteosarcoma cell model
Journal Title: Journal of Cancer Research & Therapy - Year 2014, Vol 2, Issue 6
Abstract
In osteosarcoma patients as well as in preclinical osteosarcoma animal models post-therapy detection of residual disease and of metastases in particular remains a great challenge. The therapeutic efficacy is often overestimated because disseminated tumor cells frequently persist undetectable as dormant micrometastases. This can be avoided in preclinical studies by tagging the tumor cells with reporter genes that allow their selective detection in normal tissue down to the single cell level. In the present study we made use of a lacZ reporter gene and reinvestigated the therapeutic effect of gemcitabine on subcutaneous primary tumor growth and metastasis of mouse LM8 osteosarcoma cells in syngeneic C3H mice. Furthermore we compared the sensitivity of LM8-lacZ and of non-transduced LM8 cells to gemcitabine in vitro and in vivo because it was recently demonstrated that expression of a GFP reporter gene in osteosarcoma cells altered their aggressiveness. The present study showed that, in contrast to previous reports, gemcitabine treatment did not completely eradicate metastasis although it efficiently suppressed the growth of primary tumors and macrometastases. The results also showed that minimal residual disease is not restricted to the lungs, but also occurs in the liver and the kidneys. The direct comparison of the LM8-lacZ with the LM8 cells furthermore demonstrated that constitutive expression of the lacZ reporter gene has no effect on the aggressiveness of the cells or their sensitivity to gemcitabine. The LM8-lacZ cell-derived osteosarcoma mouse model thus represents a highly sensitive and reliable model for evaluation of anticancer drug efficacy in vivo.
Authors and Affiliations
Arlt MJE, Banke IJ, Walters DK, Berndt K, Strehler EE, Born W, Fuchs B
Keywords
Related Articles
- EP ID EP547501
- DOI 10.14312/2052-4994.2014-13
- Views 88
- Downloads 0
Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide chemotherapy in breast cancer: The TEC regimen. A retrospective analysis
Background: The use of taxanes and anthracyclines in the adjuvant treatment of primary breast cancer is well established, with benefit in both disease free survival (DFS) and overall survival (OS). Several studies demons...
Improving patient data quality by integrating oncology practice and state cancer registry tumor staging information: Feasibility and future value
Background: The transition in oncology to electronic charting offers the potential to improve the quality of patient care and value of observational research. Data fields that are more complete, have common standards, an...
18F-FDG PET/CT for first follow-up post chemotherapy in lymphoma: Is it mandatory to do whole body scan?
Objective: To assess the feasibility of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scan limited to the original sites of lymphoma in 1st follow-up (F/U) post-chemotherapy...
Hyperpigmentation of the tongue, palms and soles: Rare side effect of capecitabine
Cutaneous side effects of capecitabine include hand foot syndrome which manifests as erythema, swelling and/or desquamation. We report a case on capecitabine treatment presenting with unusual hyperpigmentation of the ton...
Primary malignant giant cell tumour of the proximal tibia: a case report
Primary malignant giant cell tumour of bone is extremely rare and very few examples exist in the literature. We report a case of a 37-year-old man with a primary malignant giant cell tumour of the proximal tibia. He was...